biotech santé | e.c. and n.i.h. projects : double your funding opportunities by claire skentelbery...

33
Les points sur les i Dr Claire SKENTELBERY – Secretary General, European Biotechnology Foundation Prof. J. BALTHAZART and Dr Julie BAKKER, ULg-GIGA Neurosciences Isabelle RAUSIN, ULg-Interface and Jérôme EECKHOUT, ULg-ARD Health researchers : double your funding opportunities and those of your U.S. partners, by targeting jointly E.C. and N.I.H. projects

Upload: liege-creative

Post on 29-Jun-2015

282 views

Category:

Health & Medicine


0 download

DESCRIPTION

A joint organization of LIEGE CREATIVE, Interface Entreprises-Université Liège and GIGA, based on shared experiences and available support in order to help researchers accessing these funding opportunities.

TRANSCRIPT

Page 1: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Les points sur les i

Dr Claire SKENTELBERY – Secretary General, European Biotechnology Foundation Prof. J. BALTHAZART and Dr Julie BAKKER, ULg-GIGA Neurosciences Isabelle RAUSIN, ULg-Interface and Jérôme EECKHOUT, ULg-ARD

Health researchers : double your funding opportunities and those of your U.S. partners, by targeting jointly E.C. and N.I.H. projects

Page 2: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Avec le soutien de :

Page 3: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

15.2.2012 www.european-biotechnology.net 1

Building transatlantic research partnerships Claire Skentelbery European Biotechnology Network

Page 4: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Mission for today

•  Introduce European Biotechnology Network •  Understand tools available to build US

research partnerships •  Suitability for your work •  Plan 2012 opportunities •  Get to work!

15.2.2012 www.european-biotechnology.net 2

Page 5: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Getting introduced

•  Cross sectoral network in biotech •  Mission to facilitate partnership •  Delivering biotechnology – critical mass,

accelerated pace •  Biotechnology Funding Hub •  Strong focus on SME/industry inclusion •  Global focus for Europe

15.2.2012 www.european-biotechnology.net 3

Page 6: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Liege as a Network member •  For researchers and support staff •  Sign up to the Network each and every one! •  Free subscription to European Biotechnology

News – sign up to get your personal copy •  Funding Hub news – get the latest updates •  Free access to Network events/training •  Priority speaker places at events •  Direct assistance in project development •  Hub around which we can build projects

15.2.2012 www.european-biotechnology.net 4

Page 7: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Offer today •  Doing the business in the US!

–  March 29th, Brussels –  Small intensive workshop –  Logistics of building a successful US partnership –  €100 Corporate members

•  Building Transatlantic partnerships –  March 30th, Brussels –  NIH, EC, DoD, Gates Foundation –  Broader look at funding and experiences –  2 free places for Corporate members

15.2.2012 www.european-biotechnology.net 5

Page 8: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Biotechnology Funding Hub

•  Track funding open to SMEs in Europe; EC, Eurostars, eurotransbio, NIH, DoD

•  Mission to build collaborative partnerships •  Work with members to find projects and

develop proposals •  Training/advice/signposting •  Skype/phone surgeries

15.2.2012 www.european-biotechnology.net 6

Page 9: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Opportunities

•  National Institutes of Health

•  Department of Defense

•  Last call in FP7

15.2.2012 www.european-biotechnology.net 7

Page 10: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

DoD 2012 – in a nutshell •  Secret funding tool – wide funding range •  Projects, fellowships – open to global application •  Few active in Europe, almost all in UK •  Significant opportunities for partnered applications:

–  Across all biology –  Diagnostics, vaccines, disease management, real

time & remote technologies –  Projects in Europe include breast cancer,

immunotherapy, lung cancer etc. 8 topics currently open

www.grants.gov 15.2.2012 www.european-biotechnology.net 8

Page 11: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

FP7 2012 – in a nutshell

– Last call in 2012 – Lots of support in Liege – Opportunity to engage US partners for EC

projects - € directly from Brussels – Strong SME partnership opportunity – EBN working with NIH to matchmake

research for FP7

15.2.2012 www.european-biotechnology.net 9

Page 12: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

NIH: Where to start? •  NIH enormous research and funding platform •  Aim of talk to address from practical perspective

–  What is it? –  Opportunities for me –  How to access projects –  Chances of success –  Best approach –  Finding partners –  Who can help me?

15.2.2012 www.european-biotechnology.net 10

Page 13: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

What is NIH? •  NIH’s mission is to seek fundamental knowledge about

the nature and behaviour of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability.

•  Broad programme – basic-applied/clinical research •  $31.2 billion annual budget – squeezed in 2011/12

15.2.2012 www.european-biotechnology.net 11

Page 14: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Institutes of the NIH

•  27! •  Cancer, eye, Heart lung and blood, human genome,

ageing, alcohol abuse, allergy & infectious disease, arthritis & skin disease, imaging and bioengineering, child health, deafness & communication disorders, dental & craniofacial, diabetes, digestive & kidney diseases, drug abuse, env health, general medical sciences, mental health, neurological disorders & stroke, nursing, rare/neglected diseases

•  New - National Center for Advancing Translational Sciences’

15.2.2012 www.european-biotechnology.net 12

Page 15: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Each Institute has…

•  Own mission and structure •  Own research funding programme and budget •  Dedicated funding or joint funding with other

Institutes •  Budget varies hugely

15.2.2012 www.european-biotechnology.net 13

Page 16: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Opportunities open for me?

•  Focus on main funding programmes suitable •  Programmes launched – open 4 years •  3 deadlines/year – multiple application

opportunities •  Main programmes open to non-US application For non-US success, must either:

– Be not available in US – Significant benefit to US research

15.2.2012 www.european-biotechnology.net 14

Page 17: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Programme announcements (PA) •  General areas of high priority •  Proposals submitted at any time of year •  Evaluated 3 times/year •  Evaluation timescale:

– Scientific merit review: 2-3 months – Advisory Council: 4-5 months – Earliest start: 6-7 months

720 PAs open NOW!

15.2.2012 www.european-biotechnology.net 15

Page 18: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Requests for Application (RFA)

•  More specific research applications •  Often single deadline

92 RFAs open now!

15.2.2012 www.european-biotechnology.net 16

Page 19: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Project types - R21

– Exploratory, groundbreaking research – Max 2 years – Max $275,000 – Encouraged to contact NIH during

development stage

15.2.2012 www.european-biotechnology.net 17

Page 20: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Project types – R01 –  ‘Original’ proposal type –  PI nominates topic and focus within programme

announcement –  Covers salary, equipment, consultants, contract

services, indirect costs, travel –  No max cost BUT:

•  €25,000 modules up to module limit of $250k •  Max 5 periods – usually 12 months each •  All non-US applicants must have detailed budget

–  1 resubmission allowed –  Encouraged to contact NIH

15.2.2012 www.european-biotechnology.net 18

Page 21: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Project types - P01

•  Research program projects •  Broad based •  Multidisciplinary •  Long term •  All address different elements of common

objectives •  Industry encouraged – non-US also •  No budget max unless stated

15.2.2012 www.european-biotechnology.net 19

Page 22: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Funding level/success rates? Varies between Institute: 2010 examples •  NCI: 17% - $516 million •  NIAID (allergy/infectious disease): 24% - $506 million •  NHLBI (heart/lung/blood): 20% - $416 million •  NIGMS (general): 27% - $336 million •  NIDDK (diabetes/digestive/kidney): 26% - $333 million This counts project renewal: higher % for those New project: More like 10% success

15.2.2012 www.european-biotechnology.net 20

Page 23: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Proposal contents

•  Pleasingly similar between all! •  Get familiar with PHS398 – core example

15.2.2012 www.european-biotechnology.net 21

Page 24: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Proposal core elements – Budget for initial/whole – Research plan:

• Aims • Strategy – see next slide •  Inclusion – women/minorities • Enrolment • Agent research • Leadership plan • Consortium/contractual plan

15.2.2012 www.european-biotechnology.net 22

Page 25: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Research strategy contents

•  Significance (problem, scientific advance, impact)

•  Innovation (changes to current practice, novelty and advantage)

•  Approach (strategy, method, analyses, data collection, risk management, hazards)

•  Preliminary studies for new applications No max length: detailed, clear and concise!

15.2.2012 www.european-biotechnology.net 23

Page 26: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Example Programme announcement

15.2.2012 www.european-biotechnology.net 24

Page 27: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

PA cont

15.2.2012 www.european-biotechnology.net 25

Page 28: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

PA cont

15.2.2012 www.european-biotechnology.net 26

Page 29: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Quick summary

•  Each call VERY detailed •  Expectations listed •  Eligibility defined •  Direct contact details for each •  Deadlines •  All hyperlinked

15.2.2012 www.european-biotechnology.net 27

Page 30: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Information overload?

•  Looked at: –  Institutes – Funding programmes – Project types – Success rates

•  What now?

15.2.2012 www.european-biotechnology.net 28

Page 31: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

If I was doing this…….

•  First time European applicant? •  Find suitable call topic •  Find European organisations already playing in

US – several in the room! •  Find US partners you KNOW and are active in

NIH •  Understand history of funding in this area •  Try and join/develop US-led proposal •  Go prepared to a key US conf and partner

15.2.2012 www.european-biotechnology.net 29

Page 32: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

Resources to use

•  Searchable database on NIH website http://projectreporter.nih.gov/reporter.cfm •  Many funding reports available •  Find groups active in your field – great starting

point

15.2.2012 www.european-biotechnology.net 30

Page 33: Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

15.2.2012 www.european-biotechnology.net 31

Thank you"

Good hunting!"